KORTUC Related Reference List:
Clinical Trial
Nimalasena S, et al. Intratumoral hydrogen peroxide with radiation therapy in locally advanced breast
cancer: Results from a Phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2020 Nov; 15 108(4): 10191029
Clinical Research
Tsuzuki A, et al. Evaluation of changes in tumor shadows and micocalcifications on mammography
following KORTUC II, a new radiosensitization treatment without any surgical procedure for elderly
patients with stage I and II breast cancer. Cancers (Basel). 2011 Sep; 3(3): 3496-3505
Yaogawa S, et al. Serial assessment of therapeutic response to new radiosensitization treatment Kochi
Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II), in patients with stage
I/II breast cancer using breast contrast-enhanced magnetic resonance imaging. Cancers (Basel). 2015
Dec; 8(1)Hayashi N, et al. Computed tomography demonstration of the production of oxygen gas following
intratumoral injection of a new radiosensitizer (KORTUC) for patients with breast cancer – Is
intratumoral injection not an ideal approach to solve the major problem of tumor hypoxia inradiotherapy? Cancers (Basel). 2016 Apr; 8(4): 43
Clinical Experience
Ogawa Y, et al. New radiosensitization treatment (KORTUC I) using hydrogen peroxide solutionsoaked gauze bolus for unresectable and superficially exposed neoplasms. Oncol Rep. 2008 June;
19(6): 1389-1394
Ogawa Y, et al. Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium
hyaluronate for topical tumor injection: A new enzyme targeting radiosensitization treatment Kochi
Oxydol-Radiation Therapy for Unresectable Carcinomas, Type II (KORTUC II). Int J Oncol. 2009
Mar; 34(3): 609-618
Hitomi J, et al. Non-surgical therapy and radiologic assessment of stage I breast cancer treatment withnovel enzyme-targeting radiosensitization – Kochi Oxydol-Radiation Therapy for Unresectable
Carcinomas, Type II (KORTUC II). Exp Ther Med. 2010 Sep; 1(5): 769-775

Miyatake K, et al. Non-surgical care for locally advanced breast cancer: Radiologically assessed
therapeutic outcome of a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-Radiation
Therapy for Unresectable Carcinomas, Type II (KORTUC II) with systemic chemotherapy. Oncol Rep.
2010 Nov; 24(5) Sep: 1161-1168
Ogawa Y, et al. Safety and effectiveness of a new enzyme-targeting radiosensitization treatment(KORTUC II) for intratumoral injection for low-LET radioresistant tumors. Int J Oncol. 2011 Sep;
39(3): 553-560
Aoyama N, et al. Therapeutic response to a new enzyme-targeting radiosensitization treatment(KORTUC-SC) for patients with chemotherapy resistant supraclavicular lymph node metastasis. JCancer Res & Ther. 2013 Oct; 1(9): 215-219
Nishioka A, et al. Safety and efficacy of image-guided enzyme-targeting radiosensitization andintraoperative radiotherapy for locally advanced unresectable pancreatic cancer. Oncol Lett. 2014 Jul;
8(1): 404-408
Ogawa Y, et al. Non-surgical breast-conserving treatment (KORTUC-BCT) using a newradiosensitization method (KORTUC II) for patients with stage I or II breast cancer. Cancers (Basel).
2015 Nov; 7(4): 2277-2289
Aoyama N, et al. Possible adverse events of non-surgical breast-conserving treatment (KORTUCBCT) using a new radiosensitization method (KORTUC II) for patients with stage I and II breastcancer. Cancer Res & Oncol. 2016 ; 2(2): 014
Aoyama N, et al. Therapeutic response to a novel enzyme-targeting radiosensitization treatment(Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breastcancer. Oncol Lett. 2016 Jul; 12(1): 29-34
Aoyama N, et al. Therapeutic response to a novel enzyme-targeting radiosensitization treatment(KORTUC II) for residual lesions in patients with stage IV breast cancer, following induction
chemotherapy with epirubicin and cyclophosphamide or taxane. Oncol Lett. 2017 Jan; 13(1): 69-76
Aoyama N, et al. Therapeutic results of an enzyme-targeting radiosensitization treatment, Kochi
Oxydol-Radiation Therapy for Unresectable Carcinomas, in patients with stage I primary breast cancer,Oncol Lett. 2017 Jun; 13(6): 4741-4747

Shibamoto Y, et al. Definitive radiotherapy with SBRT or IMRT boost for breast cancer : Excellent
local control and cosmetic outcome. Technol Cancer Res Treat. 2018 Aug; 17: 1-7
Mio Nakata, et al. High-dose-rate interstitial brachytherapy with hypoxic radiosensitizer KORTUC IIfor unresectable pelvic sidewall recurrence of uterine cervical cancer: a case report. J ContempBrachytherapy. 2020 Dec;12(6):606-611. DOI: 10.5114/jcb.2020.101695
Shiro Obata, et al. Actual practice of Kochi oxydol radiation therapy for unresectable carcinomas byintra-tumoral administration of hydrogen peroxide as a radiosensitizer. Mol Clin Oncol. 2022
Mar;16(3):68.

Basic Research (Cellular Level)
Ogawa Y, et al. Mechanism of apoptotic resistance of human osteosarcoma cell line, HS-Os-1, against
irradiation. Int J Mol Med. 2003 Oct; 12(4): 453-458
Ogawa Y, et al. Apoptotic-resistance of the human osteosarcoma cell line HS-Os-1 to irradiation isconverted to apoptotic-susceptibility by hydrogen peroxide: a potent role of hydrogen peroxide as anew radiosensitizer. Int J Mol Med. 2003 Dec; 12(6):845-850
Ogawa Y, et al. Reactive oxygen species-producing site in radiation-induced apoptosis of humanperipheral T cells: Involvement of lysosomal membrane destabilization. Int J Mol Med. 2004 Jan;
13(1): 69-73
Ogawa Y, et al. Comparison of radiation-induced reactive oxygen species formation in adult articularchondrocytes and that in human peripheral T cells: Possible implication in radiosensitivity. Int J Mol
Med. 2003 Apr; 11(4): 455-459
Kariya S, et al. Combination treatment of hydrogen peroxide and X-rays induces apoptosis in humanprostate cancer PC-3 cells. Int J Radiat Oncol Bio Phys. 2009 Oct; 75(2): 449-454
Fang Y. Hydrogen peroxide enhances radiation-induced apoptosis and inhibition of melanoma cellproliferation. Anticancer Res. 2013 May; 33(5): 1799-1807
Fujita S, et al. Apoptotic induction mechanism of X-ray irradiation combined with hydrogen peroxide.
Radiat Environ & Med. 2019 Apr; 8(2): 85-93

Abbasi A, et al. Hyaluronic acid optimises therapeutic effects of hydrogen peroxide-induced oxidative
stress on breast cancer. J Cellular Physiol. 2021 Feb; 236(2): 1494-1514
Basic Research (Animal Model)
Tokuhiro S, et al. Development a novel enzyme-targeting radiosensitizer (KORTUC) containinghydrogen peroxide for intratumoral injection for patients with low linear energy transfer radioresistantneoplasms. Oncol Lett. 2010 Nov; 1(6): 1025-1028
Akima N, et al. New enzyme-targeting radiosensitizer (KORTUC) containing hydrogen peroxide &sodium hyaluronate for intra-tumoral injection using mice transplanted with SCCVII tumor. Int JCancer Res Clin Oncol. 2016 Mar; 3(2): 048
Morita-Tokuhiro S, et al. Development of a novel enzyme-targeting radiosensitizer (New KORTUC)
using a gelatin-based hydrogen instead of a sodium hyaluronate. Cancers (Basel). 2016 Jan; 8(1)Takaoka T, et al. Biological effects of hydrogen peroxide administered intratumorally with or without
irradiation in murine tumors. Cancer Sci. 2017 Sep; 108(9): 1787-1792
Iwashita T, et al. Endoscopic ultrasound-guided fine needle injection of hydrogen peroxide into thepancreas: Feasibility and tolerability study using survival porcine model. Ultrasound Med Sci. 2019Feb; 45(2): 579-585
ReviewOgawa Y. Paradigm shift in radiation biology/radiation oncology – Exploitation of the “H2O2” effectfor radiotherapy using Low-LET (Linear energy transfer) radiation such as X-rays and high-energy
electrons. Cancers. 2016 Feb; 8(3):28